The prevalence of FGFR3 gene aberrations is highest in urothelial carcinomas (18% of cases), followed by uterine carcinosarcoma (14%), esophageal (5%), ovarian (5%), and endometrial (4%) cancers (23–25). Here, FGFR3 is linked to urothelial carcinoma.